^
Association details:
| Biomarker: | FAT4 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FAT4 mutation as a potential predictive biomarker for immunotherapy combined with anti-angiogenic therapy in MSS metastatic colorectal cancer.
Published date:
05/26/2022
Excerpt:
Significant difference was detected between FAT4 mutation (FAT4-MUT) and FAT4 wildtype (FAT4-WT) regarding DCB (100%, 4/4 vs 17%, 1/7, P = 0.0152) and progress-free survival (median PFS, 13.8 months vs 2.8 months, LogRank P = 0.003)….Our findings indicated that FAT4 mutation serves as a potential novel biomarker correlated with a better response to immunotherapy combined with anti-angiogenic therapy in MSS metastatic CRC...
DOI:
10.1200/JCO.2022.40.16_suppl.e15504
